Published in

Nature Research, Nature Genetics, 3(49), p. 416-425

DOI: 10.1038/ng.3787



Export citation

Search in Google Scholar

Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets

Journal article published in 2017 by Ca A. Wang, Es S. Wan, Nj J. Wareham, Jh H. Zhao, Nick Shrine, Jf F. Wilson ORCID, María Soler Artigas, Rg G. Walters ORCID, Am Mesut Erzurumluoglu ORCID, Boris Noyvert, Lara Bossini-Castillo, Ma'en Obeidat ORCID, María Soler Artigas, Matthias Wielscher, Michael A . Portelli and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO


The stage 1 (UK BiLEVE) genome-wide association results for FEV1, FVC and FEV1/FVC are available from UK Biobank at The sources of all other data utilised in this study can be found in the Online Methods and Supplementary Note. 6 Months embargo from publication. ; Chronic Obstructive Pulmonary Disease (COPD) is characterised by reduced lung function and is the third leading cause of death globally. Through genome-wide association discovery in 48,943 individuals, selected from extremes of the lung function distribution in UK Biobank, and follow-up in 95,375 individuals, we increased the yield of independent signals for lung function from 54 to 97. A genetic risk score was associated with COPD susceptibility (odds ratios per standard deviation of the risk score (~6 alleles) (95% confidence interval) 1.24 (1.20-1.27), P=5.05x10^-49) and we observed a 3.7 fold difference in COPD risk between highest and lowest genetic risk score deciles in UK Biobank. The 97 signals show enrichment in development, elastic fibres and epigenetic regulation pathways. We highlight targets for drugs and compounds in development for COPD and asthma (genes in the inositol phosphate metabolism pathway and CHRM3) and describe targets for potential drug repositioning from other clinical indications. ; This work was funded by a Medical Research Council (MRC) strategic award to M.D. Tobin, I.P. Hall, D. Strachan and L.V. Wain (MC_PC_12010). This research has been conducted using the UK Biobank Resource under Application Number 648. This article presents independent research funded partially by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This research used the ALICE and SPECTRE High Performance Computing Facilities at the University of Leicester. Additional acknowledgements and funding can be found in the Supplementary Information. ; Peer-reviewed ; Post-print